Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum.
about
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimizationImpact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.A nested real-time PCR assay for the quantification of Plasmodium falciparum DNA extracted from dried blood spots.Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model.The dynamics of naturally acquired immunity to Plasmodium falciparum infectionEvaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionTime-to-infection by Plasmodium falciparum is largely determined by random factors.Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.Factors determining the occurrence of submicroscopic malaria infections and their relevance for control.Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Synergism from combinations of infection-blocking malaria vaccinesErythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity.Density-dependent blood stage Plasmodium falciparum suppresses malaria super-infection in a malaria holoendemic populationChallenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccinesDecreased growth rate of P. falciparum blood stage parasitemia with age in a holoendemic population.In vitro and in vivo combination of cepharanthine with anti-malarial drugs.Controlled human blood stage malaria infection: current status and potential applications.Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships.Disease Severity and Effective Parasite Multiplication Rate in Falciparum Malaria.Extent and Dynamics of Polymorphism in the Malaria Vaccine Candidate Reticulocyte-Binding Protein Homologue-5 in Kalifabougou, Mali
P2860
Q26830528-7167E0D5-256D-4EBA-9355-FB67B00D5FD3Q33974904-AAEAAE1D-D60B-4D62-A296-821F543AC478Q34340144-454B67B7-C965-471C-976C-2C95251D1F29Q34374622-A3E4BE14-59C2-479A-9944-50AA0679FB32Q34456035-81D84F34-BBD7-4311-9DAC-4948F6CDFB70Q34687174-EC392180-9DB9-4B1F-A98A-A1D1E833D8CDQ35030175-44FE72CA-FE10-4B02-BFE9-9A4CF3FDEA13Q36391845-49162BC6-37C1-4860-861C-974B43B82748Q36393102-3E9D8497-921C-41F2-9A97-FC1535165E80Q36503207-51FE6AA5-D9D1-4F32-BE06-3BFA26458E04Q36871970-86B2E108-196C-47E5-BD2F-1D3367C81078Q37151822-4BF24C12-2381-4B4E-99F7-DD88A122A0AEQ37202344-B21AD05C-E1F6-4BBC-BDE6-87A7E2710E0EQ37287640-C2185587-41FF-4BDF-BE32-86465A1B38FDQ37530299-8555DD2C-8383-47B4-83B3-CCFB250189F3Q37635135-21FE4437-3B22-42F3-9E9E-B3DADC00DD92Q37716687-915D51D9-F02F-4F95-9825-58EE00E597CEQ38001604-63FD857E-F340-4A80-934B-0057AD468595Q41620472-34D67B44-652F-4F1B-8DC0-6B03EF04DBCEQ48020791-802D20C2-5D17-4C6F-8453-0B8A86AB1AE3Q56369001-25698FC8-38C9-471D-813B-5988277FD66A
P2860
Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Substantially reduced pre-pate ...... nity to Plasmodium falciparum.
@en
Substantially reduced pre-pate ...... nity to Plasmodium falciparum.
@nl
type
label
Substantially reduced pre-pate ...... nity to Plasmodium falciparum.
@en
Substantially reduced pre-pate ...... nity to Plasmodium falciparum.
@nl
prefLabel
Substantially reduced pre-pate ...... nity to Plasmodium falciparum.
@en
Substantially reduced pre-pate ...... nity to Plasmodium falciparum.
@nl
P2093
P2860
P50
P356
P1476
Substantially reduced pre-pate ...... nity to Plasmodium falciparum.
@en
P2093
A D Douglas
A V S Hill
S J Draper
P2860
P304
P356
10.1093/INFDIS/JIR033
P407
P577
2011-05-01T00:00:00Z